LENSAR (NASDAQ:LNSR) Posts Quarterly Earnings Results, Beats Estimates By $0.26 EPS

LENSAR (NASDAQ:LNSR) announced its quarterly earnings data on Thursday. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.26, Zacks reports. LENSAR had a negative return on equity of 183.19% and a net margin of 50.94%.The company had revenue of $16.50 million for the quarter, compared to the consensus estimate of $14.65 million.

Here are the key takeaways from LENSAR’s conference call:

• Q2 revenue increased 18% year over year to $16.5 million, while recurring revenue rose 20% to $13.7 million and procedure revenue grew 23% to $10.2 million.
• LENSAR placed 10 ALLY systems during the quarter, expanding the global installed base to approximately 445 systems, with 13 ALLY systems in backlog; procedure volume increased 13% to 58,682 and U.S. procedure market share reached 24.1%.
• The company reported its strongest adjusted EBITDA performance to date at $3.6 million, supported by revenue growth, a greater mix of recurring revenue, and lower expenses; gross margin was 52% excluding a $1.1 million tariff refund.
• Cash and equivalents declined to $13.6 million from $18 million at year-end 2025, and management expects operating expenses to rise toward historical levels as it increases commercial investment, creating potential variability in EBITDA over the next several quarters.
• Management cautioned that third-quarter cataract procedure volumes are historically lower because of seasonal holidays and vacations, while rebuilding overseas distributor relationships is expected to take several quarters.

LENSAR Price Performance

LNSR stock opened at $8.27 on Friday. The company’s 50-day moving average is $5.84 and its 200-day moving average is $7.37. The stock has a market capitalization of $101.56 million, a PE ratio of -14.26 and a beta of 0.89. LENSAR has a 1 year low of $4.95 and a 1 year high of $12.96.

More LENSAR News

Here are the key news stories impacting LENSAR this week:

• Positive Sentiment: LENSAR reported earnings of $0.10 per share, versus analysts’ expected loss of $0.16 per share, while revenue reached $16.5 million, exceeding the $14.65 million consensus estimate. The company also reported a 50.94% net margin. LENSAR quarterly earnings report
• Positive Sentiment: Operational momentum was strong: LENSAR placed 10 ALLY systems during the quarter, bringing its backlog to 13 systems as of June 30. Its installed laser base rose to 445 systems, supported by 30% growth in ALLY placements. LENSAR Reports Second Quarter 2026 Results
• Positive Sentiment: Recurring revenue totaled $13.7 million, providing a more predictable revenue base and reinforcing the company’s growth in the cataract-surgery technology market. LENSAR Q2 2026 Earnings Call Highlights
• Positive Sentiment: BTIG Research raised its price target from $7 to $9 and assigned a “Buy” rating, signaling increased analyst confidence following the quarterly results. BTIG raises LENSAR price target
• Negative Sentiment: Management indicated that operating expenses are likely to rise modestly, which could limit near-term margin expansion as LENSAR invests to support system placements and growth. LENSAR signals operating expenses to rise

Analysts Set New Price Targets

A number of brokerages have weighed in on LNSR. Lake Street Capital reiterated a “buy” rating and issued a $13.00 target price on shares of LENSAR in a report on Thursday. Weiss Ratings restated a “sell (d+)” rating on shares of LENSAR in a report on Friday, August 7th. Wall Street Zen downgraded shares of LENSAR from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, BTIG Research lifted their price objective on shares of LENSAR from $7.00 to $9.00 and gave the company a “buy” rating in a research note on Thursday. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $11.00.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets boosted its holdings in LENSAR by 129.0% in the third quarter. BNP Paribas Financial Markets now owns 2,008 shares of the company’s stock worth $25,000 after acquiring an additional 1,131 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of LENSAR by 584.3% during the second quarter. JPMorgan Chase & Co. now owns 4,674 shares of the company’s stock valued at $62,000 after acquiring an additional 3,991 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of LENSAR during the second quarter worth approximately $68,000. New York State Common Retirement Fund acquired a new position in shares of LENSAR during the second quarter worth approximately $105,000. Finally, Dynamic Technology Lab Private Ltd bought a new position in shares of LENSAR in the 3rd quarter worth $125,000. 40.15% of the stock is owned by institutional investors and hedge funds.

LENSAR Company Profile

LENSAR, Inc, headquartered in Orlando, Florida, is a medical technology company specializing in advanced laser systems for ophthalmic surgery. Its flagship product, the LENSAR Laser System, combines proprietary three-dimensional imaging with precision-guided femtosecond laser delivery to perform critical steps in cataract procedures, including capsulotomy creation, lens fragmentation and corneal incisions.

Founded in 2005, LENSAR has concentrated its research and development efforts on enhancing surgical accuracy and patient outcomes in cataract treatment.